Basic Study
Copyright ©The Author(s) 2020.
World J Gastroenterol. Jun 7, 2020; 26(21): 2792-2809
Published online Jun 7, 2020. doi: 10.3748/wjg.v26.i21.2792
Figure 4
Figure 4 Cases with a statistically significant reduction of the mean relative tumor area for at least one chemotherapy scheme (the code below each diagram corresponds to the case number). Results are expressed as average ± SEM, aP < 0.05, 1-way ANOVA followed by Dunnett’s multiple comparisons test. Control group shows normal nuclei (black arrows). GEM: Gemcitabine; GEMOX: Gemcitabine + Oxaliplatin; GEM/nab-P: Gemcitabine + nab-Paclitaxel; FOLFOXIRI: 5-Fluorouracil + Folinic acid + Oxaliplatin + Irinotecan.